Survival outcomes improved with extent of tumor resection \u226575 percent for patients with grade 2 glioma<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
TUESDAY, Jan. 17, 2023 (HealthDay News) — For patients with diffuse low-grade glioma, the extent of surgical tumor resection (EOR) is associated with overall survival (OS), with improved OS seen with EOR \u00e2\u0089\u00a575 percent, according to a study published online Jan. 4 in the Journal of Clinical Oncology<\/em>.<\/p>\n Shawn L. Hervey-Jumper, M.D., from the University of California in San Francisco, and colleagues conducted a 20-year retrospective cohort study involving 392 patients with Isocitrate dehydrogenase-mutant grade 2 glioma to examine the combined effects of volumetric EOR and molecular and clinical factors on OS and progression-free survival. The OS results were validated in two external cohorts with 365 participants.<\/p>\n The researchers identified three survival risk groups using a recursive partitioning analysis. The shortest median OS was seen in two subsets of patients with astrocytoma: those with postoperative tumor volume (TV) >4.6 mL and those with preoperative TV >43.1 mL and postoperative TV of \u00e2\u0089\u00a44.6 mL. Patients with astrocytoma who had chemotherapy with preoperative TV \u00e2\u0089\u00a443.1 mL and postoperative TV \u00e2\u0089\u00a44.6 mL and patients with oligodendroglioma with preoperative TV >43.1 mL and residual TV \u00e2\u0089\u00a44.6 mL or postoperative residual volume >4.6 mL had intermediate OS. Astrocytoma patients with preoperative TV \u00e2\u0089\u00a443.1 mL and postoperative TV \u00e2\u0089\u00a44.6 mL who received no chemotherapy and oligodendroglioma patients with preoperative TV \u00e2\u0089\u00a443.1 mL and postoperative TV \u00e2\u0089\u00a44.6 mL had the longest OS. Survival outcomes were improved with EOR \u00e2\u0089\u00a575 percent.<\/p>\n “Even for oligodendrogliomas, there is no question that maximal resection is critical for enhancing survival,” Hervey-Jumper said in a statement.<\/p>\n Several authors disclosed financial ties to the biopharmaceutical, medical device, and health care industries.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n